BiomX Inc. reported its financial results for the second quarter ended June 30, 2025, on August 13, 2025. The company's cash balance and restricted cash were $15.2 million as of June 30, 2025, a decrease from $18.0 million at December 31, 2024, primarily due to net cash used in operating activities.
Net loss for Q2 2025 was $6.0 million, compared to a net income of $4.5 million for Q2 2024, mainly due to the change in the fair value of warrants issued in the March 2024 financing. Research and development expenses, net, decreased to $5.0 million from $6.9 million in Q2 2024, driven by workforce reductions and lower rent expenses, partially offset by increased costs from initiating the BX004 Phase 2b clinical trial.
BiomX estimates its cash, cash equivalents, and restricted cash are sufficient to fund operations into the first quarter of 2026. The company also highlighted positive Phase 2 results for BX211 in diabetic foot osteomyelitis, showing over 40% wound size reduction versus placebo, and confirmed that the Phase 2b trial of BX004 in Cystic Fibrosis has commenced patient dosing, with topline results expected in Q1 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.